Search

Your search keyword '"Matsubara, N."' showing total 425 results

Search Constraints

Start Over You searched for: Author "Matsubara, N." Remove constraint Author: "Matsubara, N." Search Limiters Full Text Remove constraint Search Limiters: Full Text
425 results on '"Matsubara, N."'

Search Results

1. The Duel of Magnetic Interactions & Structural Instabilities: Itinerant Frustration in the Triangular Lattice Compound LiCrSe$_2$

2. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe$_2$ investigated by $\mu^+$SR as well as neutron and X-ray diffraction

3. Neutron powder diffraction study of NaMn$_2$O$_4$ and Li$_{0.92}$Mn$_2$O$_4$: New insights on spin-charge-orbital ordering

4. Magnetism and Ion Diffusion in Honeycomb Layered Oxide K$_2$Ni$_2$TeO$_6$: First Time Study by Muon Spin Rotation & Neutron Scattering

5. Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

7. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

8. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe2 investigated by $$\mu ^+$$SR, neutron and X-ray diffraction

9. 264P Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer

10. 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

11. 1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

12. Does antimicrobial use density at the ward level influence monthly central line-associated bloodstream infection rates?

13. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

14. Surgeons' fear of getting infected by COVID19: A global survey

15. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

16. Surgeons' fear of getting infected by COVID19: A global survey

17. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

18. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe2 investigated by mu+SR, neutron and X-ray diffraction

19. Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcus aureus surveillance: a 60-month study

20. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

21. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

22. 545P First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part

24. 617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

25. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

26. 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)

27. P108 - Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

33. 1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

34. 1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study

35. 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

36. 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

38. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

39. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

40. Neutron powder diffraction study of NaMn$_{2}$O$_{4}$ and Li$_{0.92}$Mn$_{2}$O$_{4}$: Insights on spin-charge-orbital ordering

41. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

43. Screening policies, preventive measures and in-hospital infection of COVID-19 in global surgical practices

44. 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia

47. 624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

49. LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

50. 729P Prognostic value of PD-L1 status in the primary lesion as a risk factor for developing metastatic disease in localized renal cell carcinoma: A subgroup analysis of the ARCHERY study

Catalog

Books, media, physical & digital resources